Q-omics provides the consensus-scored WNT16 profile across patient tissues and cancer cell-line models. WNT16 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WNT16 is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, WNT16 RNA expression shows 12,361 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where WNT16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT16 survival associations across molecular data types. WNT16 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT16 RNA expression–survival associations across cancer types. High WNT16 expression shows unfavorable associations in KIRC, KIRP, LGG, ACC and SCLC, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WNT16 RNA expression.
This table summarizes WNT16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for WNT16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT16 shows lower tumor expression in KIRP, KIRC, READ, COAD and PRAD and higher tumor expression in LUSC. The KIRP box plot shows higher WNT16 RNA expression in normal versus tumor tissue (log2 FC = −0.224, t-test p < 0.001).
This table shows molecular features associated with WNT16 in patient tissues and cancer cell lines. In patient samples, WNT16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
